Generic · Suppository
Morphine 20 mg suppository price what pharmacies pay, and what you should
There is no weekly pharmacy acquisition cost for morphine 20 mg suppository this week. The makers, package codes, recalls and label are below.
What people paid for morphine 20 mg suppository
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Shortages
- Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)On allocation
- Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)On allocation
- Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)
- Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)Next Delivery and Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)Discontinuation of the manufacture of the drug
- Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)
- Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)
- Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)Next Delivery and Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)
- Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)Estimated recovery: TBD
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 188 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
1 company sell morphine 20 mg suppository under 1 package code (NDC).
| Maker | Package codes | Per unit |
|---|---|---|
| Bryant Ranch Prepack | 63629-2536-1 | - |
All 1 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Other morphine strengths and forms
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 10 mg extended-release capsule | $2.61 | $78.17 / 30 capsules | ||
| 20 mg extended-release capsule | $3.08 | $92.43 / 30 capsules | ||
| 30 mg extended-release capsule | Not priced this week | |||
| 60 mg extended-release capsule | Not priced this week | |||
| 15 mg extended-release tablet | $0.3100 | $9.30 / 30 tablets | ||
| 30 mg extended-release tablet | $0.4290 | $12.87 / 30 tablets | ||
| 60 mg extended-release tablet | $0.6949 | $20.85 / 30 tablets | ||
| 100 mg extended-release tablet | $0.8556 | $25.67 / 30 tablets | ||
| 200 mg extended-release tablet | $2.21 | $66.30 / 30 tablets | ||
| 4 mg/mL, 1 mL injection | $2.32 | $58.02 / 25 mL | ||
| 10 mg/mL, 1 mL injection | $2.34 | $58.56 / 25 mL | ||
| 2 mg/mL oral solution | $0.0421 | $6.32 / 150 mL | ||
| 4 mg/mL oral solution | $0.1205 | $12.04 / 100 mL | ||
| 20 mg/mL oral solution | $0.3753 | $11.26 / 30 mL | ||
| 5 mg suppository | Not priced this week | |||
| 10 mg suppository | Not priced this week | |||
| 30 mg suppository | Not priced this week | |||
| 15 mg tablet | $0.2227 | $6.68 / 30 tablets | ||
| 30 mg tablet | $0.3545 | $10.63 / 30 tablets | ||
Official label & what changed
These highlights do not include all the information needed to use MORPHINE SULFATE ORAL SOLUTION safely and effectively. See full prescribing information for MORPHINE SULFATE ORAL SOLUTION.MORPHINE SULFATE oral solution, for oral use CIIInitial U.S. Approval: 1941
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MORPHINE SULFATE ORAL SOLUTION
Risk of Medication Errors
Ensure accuracy when prescribing, dispensing, and administering Morphine Sulfate Oral Solution. Dosing errors due to confusion between mg and mL, and other morphine sulfate oral solutions of different concentrations can result in accidental overdose and death [see Dosage and Administration (2.1), Warnings and Precautions (5.1)].
Addiction, Abuse, and Misuse
Because the use of Morphine Sulfate Oral Solution exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.2)].
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of Morphine Sulfate Oral Solution, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Morphine Sulfate Oral Solution are essential [see Warnings and Precautions (5.3)].
Accidental Ingestion
Accidental ingestion of even one dose of Morphine Sulfate Oral Solution, especially by children, can result in a fatal overdose of morphine [see Warnings and Precautions (5.3)].
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of Morphine Sulfate Oral Solution and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [seeWarnings and Precautions (5.4), Drug Interactions (7)].
Neonatal Opioid Withdrawal Syndrome (NOWS)
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threating if not recognized and treated. Ensure that management by neonatology experts will be available at delivery[see Warnings and Precautions (5.5)].
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.6)].
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MORPHINE SULFATE ORAL SOLUTION
See full prescribing information for complete boxed warning.
•
Ensure accuracy when prescribing, dispensing, and administering Morphine Sulfate Oral Solution. Dosing errors due to confusion between mg and mL, and other morphine sulfate oral solutions of different concentrations can result in accidental overdose and death. (2.1, 5.1)
•
Morphine Sulfate Oral Solution exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (5.2)
•
Serious, life-threatening, or fatal respiratory depression may occur especially during initiation and following dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Morphine Sulfate Oral Solution are essential. (5.3)
•
Accidental ingestion of Morphine Sulfate Oral Solution, especially by children, can result in a fatal overdose of morphine. (5.3)
•
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.4, 7)
•
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.5)
•
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.6)
Recent major changes (as listed on the label)
Boxed Warning
|
12/2025
|
Indications and Usage (1)
|
12/2025
|
Dosage and Administration (2.3, 2.6)
|
12/2025
|
Warnings and Precautions (5.2,5.3, 5.4, 5.13, 5.15)
|
12/2025
|
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about morphine 20 mg suppository
Who makes morphine 20 mg suppository?
1 company: Bryant Ranch Prepack. See every package code.
Is morphine in shortage?
Yes - 30 products are listed as short or being discontinued. Details.
Has morphine been recalled?
188 recalls on record, 7 ongoing. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about morphine 20 mg suppository
No comments yet. Questions, tips, what worked for you - start the conversation.